Kymo Therapeutics
Hereford
About Kymo Therapeutics
Kymo Therapeutics’s ambition is to move forward Metabrain Research’s proprietary program on kynurenine metabolism (KMO) inhibitors towards clinical proof of concept, before seeking partners to complete development and ensure commercialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $11.0M
- Funding stage: Seed
- Last round: Seed (Oct 2016)
Industries & Categories
Biotechnology, Therapeutics
Canonical: https://fsome.com/organization/kymo-therapeutics-73891 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.